Dr. Do Yeon Cho
ENT (Otolaryngology) (Otolaryngology Physician)
- Medicare participating
At a glance
- Years since graduation
- 27
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 154
Licensed in Alabama since 2016, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Otolaryngology Physician primary
AL license 34719 (first issued 2016; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Alabama Hospital Birmingham, AL
Medical groups
- University of Alabama Health Services Foundation, PC (2,814 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 154
- Services billed
- 473
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Diagnostic exam of nasal passages using an endoscope | 192 | 134 |
| Established patient office or other outpatient visit, 20-29 minutes | 126 | 82 |
| New patient office or other outpatient visit, 45-59 minutes | 46 | 46 |
| Established patient office or other outpatient visit, 30-39 minutes | 24 | 23 |
| New patient office or other outpatient visit, 60-74 minutes | 17 | 17 |
| Biopsy or removal of nasal polyp or tissue using an endoscope | 16 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ipratropium Bromide Other prescribers in Birmingham, AL | 68 |
| Fluticasone Propionate Other prescribers in Birmingham, AL | 57 |
| Azelastine Hcl Other prescribers in Birmingham, AL | 47 |
| Dupixent Pen (dupilumab) Other prescribers in Birmingham, AL | 32 |
| Desloratadine | 15 |
| Doxycycline Hyclate Other prescribers in Birmingham, AL | 13 |
| Amoxicillin-Clavulanate Potass (amoxicillin/potassium clav) Other prescribers in Birmingham, AL | 11 |
| Clarithromycin | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 46 payments worth $9,654 in total to this clinician.
| Genzyme Corporation | $4,892 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $1,919 |
| Medtronic, Inc. | $1,362 |
| 3-d Matrix, Inc. | $617 |
| Aerin Medical Inc. | $592 |
| Neurent Medical Limited | $132 |
| GlaxoSmithKline, LLC. | $104 |
| Spirair, Inc. | $35.57 |
| Consulting Fee | $4,536 |
|---|---|
| Travel and Lodging | $2,643 |
| Food and Beverage | $2,475 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Jun 20, 2025 | Consulting Fee DUPIXENT · Immunology | $3,192 |
| Genzyme Corporation Jun 12, 2025 | Consulting Fee | $1,344 |
| Regeneron Healthcare Solutions, Inc. Dec 3, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to HOUSTON, TX · in-kind | $732 |
| Medtronic, Inc. Feb 20, 2025 | Travel and Lodging QUADCUT · Image Guided Surgery Products · travel to Jacksonville, FL · in-kind | $547 |
| Regeneron Healthcare Solutions, Inc. Dec 6, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to HOUSTON, TX · in-kind | $278 |
| Genzyme Corporation Jun 20, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Budapest, Hungary · in-kind | $196 |
| Regeneron Healthcare Solutions, Inc. Dec 9, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to HOUSTON, TX · in-kind | $161 |
| Regeneron Healthcare Solutions, Inc. Dec 9, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to HOUSTON, TX · in-kind | $161 |
| Medtronic, Inc. Apr 10, 2025 | Travel and Lodging travel to Jacksonville, FL · in-kind | $145 |
| Medtronic, Inc. Apr 11, 2025 | Travel and Lodging travel to Jacksonville, FL · in-kind | $145 |
All 21 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Dec 9, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to HOUSTON, TX · in-kind | $161 |
| Regeneron Healthcare Solutions, Inc. Dec 9, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to HOUSTON, TX · in-kind | $161 |
| Regeneron Healthcare Solutions, Inc. Dec 6, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to HOUSTON, TX · in-kind | $278 |
| Regeneron Healthcare Solutions, Inc. Dec 3, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to HOUSTON, TX · in-kind | $732 |
| Regeneron Healthcare Solutions, Inc. Dec 3, 2025 | Travel and Lodging DUPIXENT · IMMUNOLOGY AND INFLAMMATION · travel to HOUSTON, TX · in-kind | $35.25 |
| Genzyme Corporation Jun 20, 2025 | Consulting Fee DUPIXENT · Immunology | $3,192 |
| Genzyme Corporation Jun 20, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Budapest, Hungary · in-kind | $196 |
| Genzyme Corporation Jun 12, 2025 | Consulting Fee | $1,344 |
| Medtronic, Inc. Apr 14, 2025 | Travel and Lodging travel to Jacksonville, FL · in-kind | $27.14 |
| Medtronic, Inc. Apr 12, 2025 | Travel and Lodging travel to Jacksonville, FL · in-kind | $26.17 |
| Medtronic, Inc. Apr 12, 2025 | Travel and Lodging travel to Jacksonville, FL · in-kind | $18.42 |
| Medtronic, Inc. Apr 11, 2025 | Travel and Lodging travel to Jacksonville, FL · in-kind | $145 |
| Medtronic, Inc. Apr 11, 2025 | Travel and Lodging travel to Jacksonville, FL · in-kind | $26.63 |
| Medtronic, Inc. Apr 11, 2025 | Travel and Lodging travel to Jacksonville, FL · in-kind | $19.58 |
| Medtronic, Inc. Apr 11, 2025 | Travel and Lodging travel to Jacksonville, FL · in-kind | $18.42 |
| Medtronic, Inc. Apr 10, 2025 | Travel and Lodging travel to Jacksonville, FL · in-kind | $145 |
| Medtronic, Inc. Apr 10, 2025 | Travel and Lodging travel to Jacksonville, FL · in-kind | $19.58 |
| Medtronic, Inc. Apr 10, 2025 | Travel and Lodging travel to Jacksonville, FL · in-kind | $16.51 |
| Medtronic, Inc. Mar 17, 2025 | Travel and Lodging QUADCUT · Image Guided Surgery Products · travel to Jacksonville, FL · in-kind | $35.07 |
| Medtronic, Inc. Feb 20, 2025 | Travel and Lodging QUADCUT · Image Guided Surgery Products · travel to Jacksonville, FL · in-kind | $547 |
| Medtronic, Inc. Feb 20, 2025 | Travel and Lodging QUADCUT · Image Guided Surgery Products · travel to Jacksonville, FL · in-kind | $35.07 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $40,985 in research payments for these studies, mostly to the institutions running them.
- A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
Eli Lilly and Company · Recruiting · NCT06338995
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.